Netflix partners with SoftBank for Japanese launch
Aug 25, 2015
Netflix is rising in the Land of the Rising Sun. When the online streaming service launches inJapan on Sept. 2., mobile provider SoftBank will exclusively offer a fully integrated Netflix experience.
says each share CANNOT be sol less than $4.60 and does not say ADS -10 common shares
EXEL Is A Buyout Candidate In The Making
By Lowenthal Capital Partners
At this juncture, an EXEL buyout could be hinged on a number of key developments. Positive OS data for Cometriq certainly tops the list. Novartis and Bristol-Meyers could be potential suitors. Strong OS data for Cometriq would undermine the commercial prospects of Opdivo and Afinitor, thus offering incentives for both companies to buy EXEL at a hefty premium in order to retain market share.
It is possible that BMY may outright buy EXEL to capitalize on the success of Cometriq, as well as possible synergies between cobimetinib and vermurafenib (Zelboraf) - which I will elucidate. Aside from Cometriq, the early stage studies of cobimetinib in combination with Zelboraf in advanced solid tumors could help attract buyout interest. Zelboraf is a relatively important product of Genentech, a subsidiary ofRoche(OTCQX:RHHBY). Thus, it is possible that EXELwould attract further buyout interest from Roche if cobimetinib is shown to complement Zelboraf for the treatment of advanced solid tumors
great buy opportunity
Bloomberg reported SGYP Talking w/ Advisors On Buyout
Synergy Pharmaceuticals Inc (SGYP.O) is talking to advisers about options including the sale of the company, Bloomberg reported, citing sources.
The company's stock was up about 10 percent at $4.21 following the report on Thursday.
The gastrointestinal drug developer, which had a market value of about $370 million onWednesday, is exploring a sale after competitor Salix Pharmaceuticals Ltd SLXP.O agreed to be bought earlier in March, the report said.